{
    "clinical_study": {
        "@rank": "23504", 
        "arm_group": [
            {
                "arm_group_label": "GL2702 GLARS-NF1 , fasted", 
                "arm_group_type": "Experimental", 
                "description": "Tamsulsoin 0.4mg"
            }, 
            {
                "arm_group_label": "Omix Ocas\u00ae , fasted", 
                "arm_group_type": "Active Comparator", 
                "description": "Tamsulsoin 0.4mg"
            }, 
            {
                "arm_group_label": "GL2702 GLARS-NF1, after meal", 
                "arm_group_type": "Experimental", 
                "description": "Tamsulsoin 0.4mg"
            }, 
            {
                "arm_group_label": "Omix Ocas\u00ae, after meal", 
                "arm_group_type": "Active Comparator", 
                "description": "Tamsulsoin 0.4mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas\u00ae in Healthy Male\n      Volunteers"
        }, 
        "brief_title": "A PK Study GL2702 GLARS-NF1 and Omix Ocas\u00ae in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "GL2702 GLARS-NF1 tablet is controlled released formulation which is invented by GL Pharm\n      Tech Corp."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20~45 years old, Healthy Adult Male Subject\n\n          -  Body Weight \u2265 50kg and Ideal Body Weight \u2264 \u00b120%\n\n        Exclusion Criteria:\n\n          -  ALT or AST > 1.25 times (Upper Normal Range)\n\n          -  Total Bilirubin > 1.5 times (Upper Normal Range)\n\n          -  CPK > 2 times (Upper Normal Range)\n\n          -  BUN or Creatinine > Normal Range\n\n          -  Systolic BP > 160mmHg or < 80mmHg, Diastolic BP > 100mmHg or < 50mmHg"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072213", 
            "org_study_id": "GL2702-103"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GL2702 GLARS-NF1 , fasted", 
                    "GL2702 GLARS-NF1, after meal"
                ], 
                "description": "0.4mg once a day", 
                "intervention_name": "GL2702 GLARS-NF1", 
                "intervention_type": "Drug", 
                "other_name": "Tamsulosin"
            }, 
            {
                "arm_group_label": [
                    "Omix Ocas\u00ae , fasted", 
                    "Omix Ocas\u00ae, after meal"
                ], 
                "description": "0.4mg once a day", 
                "intervention_name": "Omix Ocas", 
                "intervention_type": "Drug", 
                "other_name": "Tamsulosin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tamsulosin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Tamsulosin,controlled release formulation", 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jeonju-si", 
                    "country": "Korea, Republic of", 
                    "state": "Jeollabukdo", 
                    "zip": "561-712"
                }, 
                "name": "Chonbuk National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas\u00ae in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Chonbuk National University Hospital", 
            "last_name": "Min-Gul Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Pharmacokinetic parameter of tamsulosin 0.4mg", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "description": "Pharmacokinetic parameter of Tamsulosin 0.4mg", 
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetic parameter of Tamsulosin 0.4 mg", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "description": "Pharmacokinetic parameter of Tamsulosin 0.4 mg", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "description": "Pharmacokinetic parameter of Tamsulosin 0.4 mg", 
                "measure": "Vz/F", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "description": "Pharmacokinetic parameter of Tamsulosin 0.4 mg", 
                "measure": "CL/F", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }
        ], 
        "source": "GL Pharm Tech Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GL Pharm Tech Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}